Vyalev (AbbVie) is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy to address motor fluctuations in advanced Parkinson’s disease.
27 – Oct. 1, 2024 Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has launched CREXONT® (carbidopa and levodopa) extended-release ...
Results that may be inaccessible to you are currently showing.